首页/数据集/Baseline Characteristics of 2,363 prostate cancer patients included in the IHC study<sup>*</sup>.

Baseline Characteristics of 2,363 prostate cancer patients included in the IHC study<sup>*</sup>.

NIAID Data Ecosystem2026-03-08 收录

数据链接：

https://figshare.com/articles/dataset/_Baseline_Characteristics_of_2_363_prostate_cancer_patients_included_in_the_IHC_study_/1100034 数据链接链接失效反馈

官方服务：

资源简介：

*Deviations from total are due to missing data in the subcategories. (AJCC = American Joint Committee on Cancer, PSA = Prostate-specific antigen).

应用场景：

创建时间：

2014-07-10

结直肠癌复发

肿瘤生物标志物

One of the main aims of the follow-up after curative resection of colorectal cancer is the early detection and treatment of tumor recurrence. We previously demonstrated decreased preoperative soluble

Figshare2016-01-15 更新50

Paleturquoise module genes.

泛基因组分析

肿瘤生物标志物

Next-generation sequencing technology enables uniform and impartial assessment of cancer diagnoses and prognosis. However, such studies are mostly type-specific, and capturing shared genomic abnormali

Figshare2025-05-30 更新40

Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression on therapy with irinotecan og cetuximab – effect and biological markers.

结直肠癌靶向治疗

肿瘤生物标志物

Main objective: • Disease control as the sum of number of patients with CR, PR and SD. Primary endpoints: Disease control as sum of number of patients with CR, PR, and SD

NIAID Data Ecosystem20

Artificial neural network identified a 20-gene panel with promising value in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in GBM patients

GBM胶质母细胞瘤

肿瘤生物标志物

Question: Which biomarker can effectively predict the immunotherapy response and prognostic benefits of GBM patients, and how can potential responders to immune checkpoint inhibitors (ICIs) be disc

Figshare2021-02-25 更新40

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers. BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

乳腺癌药物反应

肿瘤生物标志物

Expression data from patient-derived xenografts of human triple-negative breast cancers Overall design: We used GeneChip Human 1.1 ST arrays to identify the genes differentially expressed in PDX with

NIAID Data Ecosystem20

Baseline Characteristics of 2,363 prostate cancer patients included in the IHC study<sup>*</sup>.

资源简介：

相关数据集